Neuphoria Therapeutics Inc. Common Stock (NEUP)

About NEUP

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

7

Website

www.neuphoriatx.com/

Fundamentals

1-day range

$3.72$3.84

Market cap

$21.08M

P/E (trailing)

—

P/E (forward)

-1.55

EPS (trailing)

$-8.77

Dividend yield

—

Beta

0.76

Avg. volume

199.0K

Neuphoria Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.08MP/E —
  $3.19$21.4
• CALC

  CalciMedica Inc. Common Stock

  $0.4644

  ▼ 1.19%
  Market cap $21.88MP/E —
  $0.4606$7.2
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.92MP/E —
  $0.72$3.78
• GRDX

  GridAI Technologies Corp. Common Stock

  $4.05

  ▲ 1.00%
  Market cap $19.91MP/E —
  $1.65$6.93
• RKTO

  Rocket One Inc. Common Stock

  $0.7021

  ▼ 2.76%
  Market cap $19.75MP/E —
  $0.691501$2.45
• TVRD

  Tvardi Therapeutics Inc. Common Stock

  $1.8

  ▲ 0.00%
  Market cap $23.02MP/E —
  $1.5$43.65
• BRNS

  Barinthus Biotherapeutics plc American Depositary Shares

  $0.7464

  ▲ 2.11%
  Market cap $23.08MP/E —
  $0.512$1.83

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

1.66M

Total value held

$6.60M

Institutional holders

18